GLP-1 vs GLP-2: What's the Difference, and Which One Are You On?

Is GLP-2 the same as GLP-1? Short answer: no

GLP-1 and GLP-2 share a name, a birthplace in the gut, and not much else once they leave the factory. GLP-1, or glucagon-like peptide-1, is the hormone that slows digestion, dials down appetite, and helps regulate blood sugar — it's the target of every drug in the Ozempic-Wegovy-Mounjaro-Zepbound family. GLP-2 does something almost unrelated: it tells the cells lining your small intestine to grow. One FDA-approved GLP-2 drug exists, and it treats a rare condition called short bowel syndrome, not weight or glucose. If you saw 'GLP-2' somewhere and wondered whether you'd been missing a better option, you haven't — it isn't built for what you're using GLP-1 for.

Did I get confused, or am I on the wrong medication?

Neither, most likely. The confusion is completely reasonable — the two abbreviations are one character apart, both are legitimate hormones with FDA-approved drugs named after them, and they were discovered together, which is exactly why the names rhyme. If you're taking semaglutide, tirzepatide, or liraglutide for weight or blood sugar, you're on a GLP-1 medication, and that's the correct family for that goal. Nobody prescribes teduglutide, the GLP-2 drug, for weight loss — it isn't studied for that, isn't approved for that, and doesn't work that way pharmacologically. So the question to actually settle isn't GLP-1 versus GLP-2; it's whether you're on the right GLP-1 drug and dose for you, which is a conversation worth having with the clinician managing your prescription.

What GLP-1 actually is, and which drugs count

GLP-1 is a hormone your gut releases after you eat. It nudges your pancreas to release more insulin, slows how fast food leaves your stomach, and signals fullness to your brain — which is why GLP-1 receptor agonist drugs both blunt appetite and improve blood sugar control. Several brand names carry a GLP-1 receptor agonist, and it's worth knowing which:

• Semaglutide — sold as Ozempic (type 2 diabetes) and Wegovy (chronic weight management), plus the oral tablet Rybelsus (type 2 diabetes).
• Tirzepatide — sold as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, plus obstructive sleep apnea). Tirzepatide is technically a dual agonist that activates both the GLP-1 receptor and a second gut hormone receptor called GIP, not a pure GLP-1 drug — but it's grouped with the GLP-1 class because of how it works and what it's prescribed for.
• Liraglutide — sold as Victoza (type 2 diabetes) and Saxenda (chronic weight management).

If your prescription is any of those six brand names, you're squarely in GLP-1 territory. For the dosing schedules behind each one, the GLP-1 dosage guide breaks down starting doses and titration steps by drug.

What GLP-2 actually is, and why it's not a weight-loss drug

GLP-2 is also a gut hormone, but its job is structural rather than metabolic: it promotes growth of the villi and crypts lining the small intestine, increasing the surface area available to absorb nutrients. Researchers call this effect intestinotrophic. It doesn't suppress appetite and it doesn't touch blood sugar the way GLP-1 does. The one FDA-approved GLP-2 drug, teduglutide (brand name Gattex), was approved in 2012 for adults and later extended to children age one and older, for a single indication: short bowel syndrome in people who depend on intravenous nutrition support because they've lost too much functioning intestine. A second GLP-2 drug candidate, apraglutide, is still in clinical trials for the same condition — the FDA asked its manufacturer for an additional confirmatory trial in 2025, and as of mid-2026 that trial (called STARS-2) is enrolling but apraglutide has not been approved. Neither drug has any FDA-sanctioned use in weight management or diabetes.

Why the names get confused

This is the part that actually explains the mix-up. GLP-1 and GLP-2 are both cut from the same larger protein, called proglucagon, inside specialized gut cells known as L-cells. When you eat, those cells release GLP-1 and GLP-2 together, in roughly equal amounts, as part of the same digestive signal — they were discovered side by side in the same research lineage decades ago, which is why the naming convention stuck. So the resemblance isn't a coincidence or a marketing overlap: they're molecular siblings that happened to get assigned to two completely different jobs in the body, one metabolic, one structural. That shared origin is worth knowing, if only because it means you didn't misread anything — the names really do belong to the same family tree.

Is a combined GLP-1/GLP-2 drug coming that could matter to you?

It's worth separating two different 'dual agonist' ideas here, because they get mixed up too. Tirzepatide, in Mounjaro and Zepbound, is already a dual agonist — but it pairs GLP-1 with GIP, not with GLP-2. A true GLP-1/GLP-2 dual agonist called dapiglutide has been tested in a small early-phase human trial for obesity: 54 adults over twelve weeks, published in February 2026. It was safe and showed some metabolic benefit, but the weight loss it produced didn't beat placebo by a statistically meaningful margin. That's a long way from a marketable drug, and it's not close to the effect sizes seen with semaglutide or tirzepatide. If you're looking for something on the horizon that might outperform what's already approved, this isn't it yet — the honest answer is that nothing GLP-2-related is close to changing your options.

Does GLP-2 have anything to do with perimenopause weight gain?

No — and it's a clean no, not a maybe. Short bowel syndrome, the condition teduglutide treats, is a rare structural digestive problem usually caused by extensive intestinal surgery or a congenital condition; it has no established connection to perimenopause, menopause, or midlife weight changes. The weight and metabolism shifts many women notice in their 40s and 50s are driven by declining estrogen, changing insulin sensitivity, and slower muscle-preserving metabolism — territory where GLP-1 drugs have real evidence, and GLP-2 drugs have none. If you want the fuller picture of why perimenopause makes weight harder to manage and what actually helps, the perimenopause weight-loss medication overview covers that ground.

So which GLP-1 is right for you, and where to go from here

Once GLP-2 is off the table as a consideration, the real questions are the ones you'd expect: which GLP-1 drug fits your goals, what the dosing looks like as you start, what side effects to expect, and what it costs. Semaglutide (Wegovy) and tirzepatide (Zepbound) are the two approved specifically for weight management, and they differ enough in mechanism and typical results that the choice is worth its own research rather than a coin flip.